Haleon PLC - Weybridge, Surrey-based consumer healthcare firm that spun out of GSK PLC in 2022 - Commences up to £330 million share buyback programme. Says this represents the remainder of the £500 million allocated to buybacks in 2025, announced as part of its 2024 results in February. It follows the completion of Haleon’s off-market repurchase of 44.2 million shares from Pfizer Inc for approximately £170 million, announced in March. Says the first tranche is for an up to £200 million consideration, commencing immediately and to end no later than June 26 this year. Haleon expects the buyback scheme to enhance its earnings per share, with Goldman Sachs hired to carry out the purchase of shares.
Current stock price: 386.10p, up 1.1% on Friday morning in London.
12-month change: up 16%
Copyright 2025 Alliance News Ltd. All Rights Reserved.
